▶ MAZDUTIDE · SUBTOPIC · MECHANISM
MAZDUTIDE Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Innovent Biologics dual GLP-1 and glucagon receptor agonist (IBI362), derived from oxyntomodulin lineage. Approved in China 2024 for chronic weight management. Phase 3 GLORY program ongoing.
PHARMACOKINETIC HALF-LIFE
Reported half-life for MAZDUTIDE: ~7 days (once-weekly). Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
MECHANISM CATEGORIES
MAZDUTIDE is tagged in 2 mechanism categories on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
The incretin axis encompasses GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide), gut hormones released in response to nutrient intake that account for roughly 70% of postprandial insulin secretion. Drugs targeting this axis include single GLP-1 agonists (GLP-3), dual GLP-1/GIP agonists (GLP-2), and triple GLP-1/GIP/glucagon agonists (GLP-1). The axis is the largest commercial pharma category of the 2020s and is responsible for the metabolic-medicine revolution underway in obesity, type 2 diabetes, and cardiometabolic disease.
Lipolysis is the breakdown of triglycerides in adipose tissue, driven by hormone-sensitive lipase activation downstream of cAMP elevation. GH-axis peptides (GH-axis reference) preferentially target visceral adipose. Glucagon-receptor agonism (the third arm of GLP-1) also drives hepatic lipid mobilization.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Zhao 2024 JAMA Netw Open · placebo-subtracted weight loss ~11.1% at 9 mg/wk over 24 weeks in Chinese adults.
HbA1c reduction in Chinese T2D Phase 2.
48-week Phase 3 obesity met primary endpoint; China NMPA review 2024-2025.
MECHANISM Q+A
▶ How is mazdutide different from survodutide?
Both are GLP-1/glucagon dual agonists. Mazdutide is developed primarily for the Chinese market by Innovent under license from Lilly; survodutide is Boehringer Ingelheim/Zealand's molecule for the global market. Different sequence, similar mechanism.
▶ How does it work?
Dual agonism at the GLP-1 and glucagon receptors. GLP-1 arm drives satiety + glucose-dependent insulin secretion; glucagon arm drives hepatic lipolysis + energy expenditure.
CITED LITERATURE
- Zhao H, et al.. Mazdutide IBI362 in obese Chinese adults: dose-finding phase 2. JAMA Netw Open 2024. link
- Innovent Biologics / Eli Lilly. A phase 3 study of mazdutide in Chinese participants with overweight or obesity (GLORY-1). ClinicalTrials.gov · Phase 3 2024. NCT05216575. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19